title: Severe immune thrombocytopenia during formestane treatment.
abstract: Formestane is a new aromatase inhibitor used as second-line endocrine treatment for postmenopausal women with advanced breast cancer. The most frequent side effects are local reactions. Here we report the development of immune thrombocytopenia coinciding with administration of this drug.
authors.forename: I
authors.initials: I
authors.lastname: Español
authors.forename: E
authors.initials: E
authors.lastname: Muñíz-Díaz
authors.forename: M C
authors.initials: MC
authors.lastname: Alonso
authors.forename: N
authors.initials: N
authors.lastname: Pujol-Moix
mesh_terms: D000735:Androstenedione / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017698:Postmenopause; D013921:Thrombocytopenia / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D000735:Androstenedione; C014594:formestane